Abstract
Neurodevelopmental disorders (NDs) are currently thought to be caused by either genetic defects or various environmental factors. Recent studies have demonstrated that congenital NDs can result not only from changes in DNA sequence in neuronal genes but also from changes to the secondary epigenomic modifications of DNA and histone proteins. Thus, epigenomic assays, as well as genomic assays, are currently performed for diagnosis of the congenital NDs. It is recently known that the epigenomic modifications can be altered by various environmental factors, which potentially cause acquired NDs. Furthermore these alterations can potentially be restored taking advantage of use of reversibility in epigenomics. Therefore, epigenome-based early diagnosis and subsequent intervention, by using drugs that restore epigenomic alterations, will open up a new era of preemptive medicine for congenital and acquired NDs.
Keywords: Neurodevelopmental disorder, Autism, Epigenomics, DNA methylation, Acquired, Preemptive medicine.
Current Genomics
Title:Epigenomic-Basis of Preemptive Medicine for Neurodevelopmental Disorders
Volume: 16 Issue: 3
Author(s): Takeo Kubota, Kunio Miyake, Natsuyo Hariya and Kazuki Mochizuki
Affiliation:
Keywords: Neurodevelopmental disorder, Autism, Epigenomics, DNA methylation, Acquired, Preemptive medicine.
Abstract: Neurodevelopmental disorders (NDs) are currently thought to be caused by either genetic defects or various environmental factors. Recent studies have demonstrated that congenital NDs can result not only from changes in DNA sequence in neuronal genes but also from changes to the secondary epigenomic modifications of DNA and histone proteins. Thus, epigenomic assays, as well as genomic assays, are currently performed for diagnosis of the congenital NDs. It is recently known that the epigenomic modifications can be altered by various environmental factors, which potentially cause acquired NDs. Furthermore these alterations can potentially be restored taking advantage of use of reversibility in epigenomics. Therefore, epigenome-based early diagnosis and subsequent intervention, by using drugs that restore epigenomic alterations, will open up a new era of preemptive medicine for congenital and acquired NDs.
Export Options
About this article
Cite this article as:
Kubota Takeo, Miyake Kunio, Hariya Natsuyo and Mochizuki Kazuki, Epigenomic-Basis of Preemptive Medicine for Neurodevelopmental Disorders, Current Genomics 2015; 16 (3) . https://dx.doi.org/10.2174/1389202916666150216221312
DOI https://dx.doi.org/10.2174/1389202916666150216221312 |
Print ISSN 1389-2029 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5488 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Advances in Drug Discovery against Neglected Tropical Diseases: Human African and American Trypanosomiasis
Current Medicinal Chemistry Caregiver Involvement in Sexual Risk Reduction with Substance Using Juvenile Delinquents: Overview and Preliminary Outcomes of a Randomized Trial
Adolescent Psychiatry The Role of Flavonoids in Inhibiting IL-6 and Inflammatory Arthritis
Current Topics in Medicinal Chemistry Capsaicin and Its Analogues: Structure-Activity Relationship Study
Current Medicinal Chemistry The Surgical Treatment of Diabetic Obesity
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Subclassification and Nomenclature of α- and β-Adrenoceptors
Current Topics in Medicinal Chemistry Insulin Like Growth Factor-I: A Critical Mediator of the Skeletal Response to Parathyroid Hormone
Current Molecular Pharmacology Neuromuscular Disorders in Left Ventricular Hypertrabeculation/Noncompaction
Current Pharmaceutical Design The Promises and Challenges of the Use of Genomics in the Prescription of Exercise in Hypertension
Current Hypertension Reviews Effect of Administration of Nandrolone Decanoate upon Aldosterone Concentration and Serum Na+/K+ Levels in Albino Mice
Cardiovascular & Hematological Agents in Medicinal Chemistry Sequential Comorbidity of Anxiety and Depression in Youth: Present Knowledge and Future Directions
Current Psychiatry Reviews Resistance to HIV-1 Entry Inhibitors
Current Drug Targets - Infectious Disorders Controversies of Dopamine Agonists: Somnolence, Cardiac Valvulopathy and Repetitive Behaviors
Current Drug Therapy Fatty Acids: Friends or Foe? Relation Between Dietary Fat and Insulin Sensitivity
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Excess Metabolic and Cardiovascular Risk is not Manifested in all Phenotypes of Polycystic Ovary Syndrome: Implications for Diagnosis and Treatment
Current Vascular Pharmacology The Cardiovascular Effects of Metformin: Further Reasons to Consider An Old Drug as a Cornerstone in the Therapy of Type 2 Diabetes Mellitus
Current Vascular Pharmacology Haptoglobin Phenotype May Alter Endothelial Progenitor Cell Cluster Formation in Cerebral Small Vessel Disease
Current Neurovascular Research Pharmacogenomics of Oral Antithrombotic Drugs
Current Pharmaceutical Design From Physiome to Pathome: A Systems Biology Model of Major Depressive Disorder and the Psycho-Immune-Neuroendocrine Network
Current Psychiatry Reviews Medical Treatment of Primary, Secondary, and Tertiary Hyperparathyroidism
Current Drug Safety